Skip to main content

Kuvatris Therapeutics, Inc.

PXMDDelisted Aug 8, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001811623

Kuvatris Therapeutics, Inc. was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Mar 14, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kuvatris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kuvatris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kuvatris Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Casamento Charles JDirector2,386Mar 14, 20240
Rome ZacharyDirector10,244Mar 14, 20240
Hough David W.Chief Medical Officer5,905Mar 14, 20240
Weisman Howard J.Chief Executive Officer34,748Mar 14, 20240
LaRochelle KarenDirector2,225Mar 14, 20240
Coelho John FDirector4,408Mar 14, 20240
Sheldon StephenCFO and COO10,137Mar 14, 20240
Derby Michael10% Owner25,650Nov 29, 20230
TardiMed Sciences LLC10% Owner7,336,745Sep 1, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 31, 2024 (view filing)7:55 PM ETJan 292 daysRome ZacharyDirectorSSale−811$0.48−$389.28−5.1%15.1K after
Jan 31, 2024 (view filing)5:19 PM ETJan 292 daysLaRochelle KarenDirectorSSale−78$0.48−$37.44−2.7%2.83K after
Jan 31, 2024 (view filing)5:18 PM ETJan 292 daysCoelho John FDirectorSSale−27$0.48−$12.96−0.6%4.62K after
Jan 31, 2024 (view filing)5:16 PM ETJan 292 daysWeisman Howard J.Chief Executive OfficerSSale−372$0.47−$174.84−1.0%37.7K after
Nov 29, 2023 (view filing)Nov 272 daysCoelho John FDirectorSSale−12$1.03−$12.36−0.3%4.64K after10b5-1
Nov 29, 2023 (view filing)Nov 272 daysWeisman Howard J.Chairman and CEOSSale−162$1.03−$166.86−0.4%38.0K after10b5-1
Nov 29, 2023 (view filing)Nov 272 daysDerby Michael10% OwnerSSale−185$1.03−$190.55−0.7%25.6K after10b5-1
Nov 29, 2023 (view filing)Nov 272 daysLaRochelle KarenDirectorSSale−35$1.03−$36.05−1.2%2.91K after10b5-1
Nov 29, 2023 (view filing)Nov 272 daysRome ZacharyDirectorSSale−359$1.03−$369.77−2.2%16.0K after10b5-1
Oct 30, 2023 (view filing)4:13 PM ETOct 273 daysRome ZacharyDirectorSSale−16.3K$0.1848−$3.01K−5.6%277.4K after10b5-1
Oct 30, 2023 (view filing)4:12 PM ETOct 273 daysDerby Michael10% OwnerSSale−9.18K$0.1897−$1.74K−2.0%439.2K after10b5-1
Oct 30, 2023 (view filing)4:12 PM ETOct 273 daysCoelho John FDirectorSSale−570$0.1895−$108.02−0.7%79.1K after10b5-1
Oct 30, 2023 (view filing)4:12 PM ETOct 273 daysLaRochelle KarenDirectorSSale−1.68K$0.189−$317.33−3.2%50.0K after10b5-1
Oct 30, 2023 (view filing)4:11 PM ETOct 273 daysWeisman Howard J.Chairman and CEOSSale−8.05K$0.1894−$1.52K−1.2%649.5K after10b5-1
Aug 30, 2023 (view filing)4:10 PM ETAug 28-292 daysCoelho John FDirectorSSale−797$0.5203−$414.67−1.0%79.7K after2 lots10b5-1
Aug 30, 2023 (view filing)4:09 PM ETAug 28-302 daysWeisman Howard J.Chairman and CEOSSale−44.1K$0.4659−$20.6K−6.3%657.6K after3 lots10b5-1
Aug 30, 2023 (view filing)4:09 PM ETAug 28-292 daysLaRochelle KarenDirectorSSale−2.46K$0.4979−$1.22K−4.5%51.7K after2 lots10b5-1
Aug 30, 2023 (view filing)4:09 PM ETAug 28-302 daysRome ZacharyDirectorSSale−25.6K$0.4827−$12.4K−8.0%293.7K after3 lots10b5-1
Aug 30, 2023 (view filing)4:08 PM ETAug 28-292 daysDerby Michael10% OwnerSSale−13.5K$0.4889−$6.62K−2.9%448.3K after2 lots10b5-1
Aug 23, 2023 (view filing)Aug 21-222 daysRome ZacharyDirectorSSale−50.0K$0.556−$27.8K−13.5%319.3K after2 lots10b5-1
Mar 9, 2023 (view filing)Mar 8-91 dayWeisman Howard J.Chief Executive OfficerSSale−35.9K$1.46−$52.3K−6.2%541.6K after2 lots
Mar 9, 2023 (view filing)Mar 8-91 dayRome ZacharyChief Operating OfficerSSale−33.4K$1.47−$49.0K−10.4%288.5K after2 lots
Mar 9, 2023 (view filing)Mar 9Same dayDerby MichaelExecutive ChairmanSSale−2.14K$1.43−$3.06K−0.7%324.4K after
Mar 9, 2023 (view filing)Mar 9Same dayLaRochelle KarenDirectorSSale−335$1.48−$495.8−0.8%42.4K after
Mar 9, 2023 (view filing)Mar 9Same dayCoelho John FDirectorSSale−130$1.48−$192.4−0.2%67.2K after
Mar 7, 2023 (view filing)Mar 6-71 dayWeisman Howard J.Chief Executive OfficerSSale−37.1K$1.60−$59.4K−6.0%577.5K after2 lots
Mar 7, 2023 (view filing)Mar 6-71 dayRome ZacharyChief Operating OfficerSSale−37.0K$1.60−$59.2K−10.3%321.9K after2 lots
Mar 7, 2023 (view filing)Mar 6-71 dayDerby MichaelExecutive ChairmanSSale−29.0K$1.63−$47.2K−8.1%326.6K after2 lots
Mar 3, 2023 (view filing)Mar 21 dayCoelho John FDirectorSSale−3.01K$1.93−$5.82K−4.3%67.4K after
Mar 3, 2023 (view filing)Mar 2-31 dayLaRochelle KarenDirectorSSale−8.83K$1.94−$17.1K−17.1%42.8K after2 lots
Mar 3, 2023 (view filing)Mar 2-31 dayWeisman Howard J.Chief Executive OfficerSSale−27.0K$1.92−$51.8K−4.2%614.7K after2 lots
Mar 3, 2023 (view filing)Mar 2-31 dayRome ZacharyChief Operating OfficerSSale−26.2K$1.91−$50.1K−6.8%358.8K after2 lots
Mar 3, 2023 (view filing)Mar 2-31 dayDerby MichaelExecutive ChairmanSSale−29.5K$1.91−$56.4K−7.7%355.5K after2 lots
Sep 1, 2022 (view filing)Aug 302 daysTardiMed Sciences LLC10% OwnerPPurchase+95.0K$5.25+$498.8K+1.3%7.34M afterDuplicate filing
Sep 1, 2022 (view filing)Aug 302 daysDerby MichaelExecutive ChairmanPPurchase+95.0K$5.25+$498.8K+1.3%7.34M after